Drug Profile
Research programme: serotonin 2A inverse agonists - ACADIA Pharmaceuticals
Alternative Names: ACP-106Latest Information Update: 04 Apr 2012
Price :
$50
*
At a glance
- Originator ACADIA Pharmaceuticals
- Class Small molecules
- Mechanism of Action Serotonin 2A receptor inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders; Insomnia; Parkinson's disease; Psychotic disorders; Schizophrenia
Most Recent Events
- 31 Dec 2010 No development reported - Preclinical for CNS disorders in USA (PO)
- 31 Dec 2010 No development reported - Preclinical for Insomnia in USA (PO)
- 31 Dec 2010 No development reported - Preclinical for Parkinson's disease in USA (PO)